Integrate | $17,000,000 | (Feb 13, 2026)
daypass.com | $2,000,000 | (Feb 13, 2026)
CYDELPHI | $3,000,000 | (Feb 13, 2026)
Aulos Bioscience
United States
- Larkspur, California
- 01/08/2023
- Series A
- $20,000,000
Aulos Bioscience is an immuno-oncology company revolutionizing cancer patient care through best-in-class IL-2 therapeutics computationally designed to exquisitely direct patients’ own immune systems towards killing tumor cells.
Matching world-class machine learning from founder and partner Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, AU-007, has been designed to harness the power of a patient’s own IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated class of therapeutics. AU-007 has the potential to become a best-in-class treatment for solid tumors.
The company was founded by Biolojic Design and ATP with $40M in Series A funding from ATP and is led by pioneers in the field of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit aulosbio.com.
- Industry Biotechnology Research
- Website https://aulosbio.com/
- LinkedIn https://www.linkedin.com/company/aulos-bioscience/
Maestro Tech, Inc. | $1,200,000 | (Feb 13, 2026)
Ever | $31,000,000 | (Feb 13, 2026)
Manufact (formerly mcp-use) | $6,300,000 | (Feb 13, 2026)
Reflow | $15,000,000 | (Feb 13, 2026)
Santé(US) | $7,600,000 | (Feb 13, 2026)
Alva Energy | $33,000,000 | (Feb 13, 2026)
Project Omega | $12,000,000 | (Feb 13, 2026)
Brandlight | $30,000,000 | (Feb 12, 2026)
Inertia | $450,000,000 | (Feb 12, 2026)